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SUMMARY – The aim of this retrospective study was to show the effect of clinical, pathologic, 
cytologic and therapeutic prognostic factors on treatment outcome and survival of patients suffering 
from vulvar cancer and to determine prognostic significance of each of the individual factors, their 
mutual significance and impact on survival. The study included patients treated for vulvar cancer at 
Department of Gynecology and Obstetrics, Osijek University Hospital Centre during the 2000-2011 
period. Retrospective analysis included data from patient medical files, along with their pathologic and 
cytologic findings, and oncologist findings. The study included 59 patients aged 45 to 88 years. Diag-
nosis was based on pathologic and cytologic status and staging. Univariate analysis showed the lymph 
node status, adjuvant radiotherapy, chemotherapy and clinical staging of the disease to be statistically 
significant prognostic factors for overall survival and prognosis of vulvar cancer patients. Multivariate 
analysis of independent prognostic factors for survival of vulvar cancer patients yielded lymph node 
status, adjuvant radiotherapy and chemotherapy as positive prognostic factors.
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Introduction
Vulvar cancer is a rare malignant disease of the fe-
male sexual system. If diagnosed at an early stage, it is 
curable. Survival is largely due to the absence of lym-
phatic metastases. This is primarily a disease of older 
age groups, but it is ever more common in younger 
ages, especially in the form of human papillomavirus 
(HPV) related infection, which is the source of vulvar 
intraepithelial neoplasia1. Treatment of the initial stage 
of the disease is primarily surgical, whereas radiother-
apy and chemoradiotherapy are used in the treatment 
of advanced stage of the disease2. According to recent 
data, survival significantly depends on the number of 
affected lymph nodes, size of primary lesion, depth 
of invasion, and involvement of the lymphopapular 
space3.
Vulvar cancer is a relatively rare type of cancer that 
accounts for 1% of all cancers in women and 4% of all 
gynecologic cancers. In the United States, there are 
1-2 vulvar cancer patients per 100,000 women. In 
about two-thirds of women, it occurs between 60 and 
80 years of life. Some studies show that half of the 
patients are aged over 70 years. Recently, the incidence 
of the disease has increased. The incidence is higher in 
developed than in underdeveloped countries. Howev-
er, about 15% of patients with congestive heart disease 
suffer from this disease before the age of 40. In young-
er age, the occurrence of cancer with HPV infection in 
its genesis is more common and develops from a pre-
malignant lesion (vulvar intraepithelial neoplasia). It is 
believed that about 80% of untreated premalignant 
lesions progress to invasive disease4.
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Patients and Methods
The study included patients treated for vulvar can-
cer at Department of Gynecology and Obstetrics, 
Osijek University Hospital Centre during the 2000-
2011 period. Retrospective analysis included data col-
lected from disease history, operative protocols, histo-
pathologic and cytologic findings, and oncologist find-
ings. The study included 59 patients aged 45 to 88 
years. The following prognostic factors were analyzed:
Clinical factors
•	 clinical stage (divided into four groups); and
•	 age (recorded and graphically depicted through-
out the five-year period)
Pathologic and cytologic factors
•	 histologic type of tumor;
•	 histologic grade (divided into three stages);
•	 tumor distance from surgical edge of the prepa-
ration (shown in millimeters and divided into 
groups of 0-5 mm, 6-10 mm, 11-15 mm, 16-20 
mm and >20 mm);
•	 depth of invasion (shown in millimeters and 
 divided into groups of <5 mm, 1-5 mm and 
>5 mm);
•	 tumor size (shown in centimeters and divided 
into groups of 0-1 cm, 1.1-2 cm, 2.1-3 cm, 3.1-4 
cm, 4.1-5 cm and >5 cm); and
•	 lymph node status (shown by the number of re-
moved lymph nodes and number of lymph 
nodes affected by the tumor)
Therapy factors
•	 surgical treatment; and
•	 adjuvant chemotherapy (performed/not per-
formed)
Statistical methods
Statistical analysis was performed using SPSS sta-
tistical software (Statistics for Windows 17.0, SPSS 
Inc., Chicago, USA). The level of statistical significance 
was set at p<0.05. Measured variables were shown 
graphically and in tables. The normality of distribution 
of the variables was tested by Kolmogorov Smirnov 
test. Categorical variables were expressed as number 
(frequency) and percentage (%), and continuous vari-
ables as median and interquartile range, or as arithme-
tic mean with standard deviation. To show the effect of 
particular factors on mortality, Kaplan-Meier curves 
and binary logistic regression analysis (Cox regression 
test) were used. Also, the χ2-test was used to assess dif-
ferences among particular factors and mortality.
Results
The survey involved 59 subjects. Of the total number 
of patients, 16 patients died and overall survival rate was 
72.9%. Figure 1 shows Kaplan-Meier overall survival 
curve. Recurrence occurred in 17 (28.8%) patients with-
in a mean of 5.6 months. Disease recurrence within 6 
months was recorded in two (11.8%) patients and with-
in 12 months in eight (47.1%) patients (Table 1).
Table 1. Follow-up according to outcome
Mean (SD) Minimum Maximum
Months to 








6.61 (15.831) 0 79
Fig. 1. Kaplan-Meier overall survival curve.
Most cases (37%) were diagnosed with the Fédéra-
tion Internationale de Gynécologie et d’Obstétrique 
(FIGO) stage II, followed by FIGO stage I (32%), 
FIGO stage III (27%) and FIGO stage IV (4%). Fig-
I. Miljanović-Špika et al. Prognostic factors for vulvar cancer
Acta Clin Croat, Vol. 60, No. 1, 2021 27
Fig. 2. Kaplan-Meier curve of patient survival according 
to FIGO staging.
Fig. 3. Kaplan-Meier survival curve with tumor size  
as a predictor.
Fig. 4. Kaplan-Meier survival curve according to tumor 
grade.
Fig. 5. Kaplan-Meier survival curve with mode  
of surgical treatment as a predictor.
Fig. 6. Kaplan-Meier survival curve with tumor 
distance from the edge as a predictor.
Fig. 7. Kaplan-Meier survival curve  
with depth of invasion as a predictor.
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ure 2 shows Kaplan-Meier curve of patient survival 
according to FIGO stage. None of the FIGO IV pa-
tients survived for more than 14 months. In the FIGO 
II and III groups, the five-year survival rate was equal-
ly poor (about 45%), whereas none of the patients with 
FIGO stage I died. There was a statistically significant 
difference in survival between FIGO I stage and all 
other FIGO stages (p<0.001), but on multivariate 
analysis, clinical stage did not prove to be an indepen-
dent prognostic factor. FIGO stage I has the best 
prognosis in five-year survival.
The largest number of study patients had tumor 
size of 1-2 cm (39%), followed by patients with tumor 
size of 2-3 cm (20%), 3-4 cm (15%), 4-5 cm (5%), 
while 10% of patients had tumor size >5 cm.
Figure 3 shows Kaplan-Meier survival curve with 
tumor size as a predictor. The best survival was record-
ed in patients with the smallest tumor size 1-2 cm 
(80%), while those with tumor size >6 cm had poor 
survival (about 20%). Tumor size was not found to be 
a statistically significant factor (p=0.122). Multivariate 
analysis did not yield tumor size as an independent 
prognostic factor.
Figure 4 shows Kaplan-Meier curve of survival ac-
cording to tumor grade. The graph shows that moder-
ately differentiated tumors had poor prognosis and 
overall survival of up to 32 months, while five-year 
survival in well-differentiated tumors was about 50%. 
Difference in survival due to histologic grade did not 
reach statistical significance on either univariate or 
multivariate analysis (p=0.320).
Radical vulvectomy was performed in more than 
half of the patients (56%). Vulvectomy was performed 
with bilateral lymphadenectomy in 22% and by exci-
sion in 12% of cases. Other methods of surgical treat-
ment were represented by less than 10%.
Figure 5 shows Kaplan-Meier survival curve with 
type of surgical treatment as a predictor. Vulvectomy 
with bilateral lymphadenectomy proved to be the most 
effective method of surgical treatment, then radical 
vulvectomy and excision, and hemivulvectomy. The 
method of surgical treatment was not a statistically 
significant factor for prognosis (p=0.222).
In the majority of patients (49%), tumor distance 
from the edge was 0 to 5 mm, followed by patients with 
tumor distance greater than 20 mm (27%). The Kaplan-
Meier survival curve for tumor distance from the edge 
as a predictor showed the best survival for patients with 
greater tumor distance from the edge of the preparation. 
If the tumor was 20 mm or more far from the edge of 
the preparation, survival was about 70%, whereas in 
those with the tumor 6 mm far from the edge survival 
was about 40%. Tumor distance from the edge of the 
preparation was not a significant factor on either uni-
variate or multivariate analysis (p=0.122) (Fig. 6).
The majority (57%) and only 9% of patients had 
the depth of invasion of 1-5 mm and <1 mm, respec-
tively. The Kaplan-Meier survival curve with the depth 
of invasion as a predictor shows poor survival rates in 
those with greater depth of tumor invasion in the stro-
ma. At the depth of invasion of 2 mm and 3 mm, sur-
vival was about 70% and 50%, respectively. The longest 
survival was recorded in patients with the depth of 
Fig. 8. Kaplan-Meier survival curve of positive lymph 
nodes.
Fig. 9. Kaplan-Meier survival curve with adjuvant 
radiotherapy and chemotherapy as a predictor.
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invasion of <1 mm; in this group, only one patient died 
during the seven-year follow-up. The depth of invasion 
did not prove to be a statistically significant prognostic 
factor on either univariate or multivariate analysis 
(p>0.236) (Fig. 7).
Out of a total of 59 subjects, lymphadenectomy was 
performed in 44 patients. Of these, lymph nodes were 
negative in 28 (63.7%) and positive in 16 (36.3%) pa-
tients. On average, 16 lymph nodes were removed per 
lymphadenectomy, with 2.5 positive lymph nodes. 
Overall survival was 75.0% in the group of patients with 
negative lymph nodes and 56.3% in the group of pa-
tients with positive lymph nodes. Difference in survival 
according to lymph node status was statistically signifi-
cant (p=0.045). On multivariate analysis, lymph node 
status was shown to be an independent prognostic fac-
tor (Fig. 8). In the group with positive lymph node sta-
tus there was a statistically significant increase in the 
number of deaths. Positive lymph node status was ob-
served in 36.4% of cases, with 43.7% mortality rate.
Kaplan-Meier survival curve with adjuvant radio-
therapy and chemotherapy as a predictor shows that 
patients who did not receive adjuvant irradiation and 
chemotherapy had better survival (about 90%), while 
those having received adjuvant irradiation and chemo-
therapy had poor survival (about 30%). Adjuvant irra-
diation and chemotherapy proved to be a statistically 
significant factor on univariate analysis (p=0.002) and 
an independent prognostic factor on multivariate anal-
ysis (p=0.014) (Fig. 9).
To assess the effect of independent factors on the 
likelihood that patients will die, binary logistic regres-
sion analysis was performed. The model contained 9 
independent factors. The complete model of all nine 
factors was statistically significant (χ2 (N=59)=39.454; 
p<0.01), which indicates that the model successfully 
differentiated deaths. As shown in Table 2, two of the 
nine predictors were found to be equally significant 
(lymph node status and adjuvant therapy) for this 
model. The most important individual predictor was 
Table 2. Binary logistic regression analysis of histologic type, staging, type of treatment, size and local tumor progression
Parameter B SE Wald df Sig. Exp (B) 95% CI for Exp (B)Lower Upper
Histologic type (1) 38.777 44683.695 0.000 1 0.999 6.931E16 0.000 .
Histologic type (2) 19.810 41760.448 0.000 1 1.000 4.011E8 0.000 .
Histologic grade (1) -0.283 1.125 0.063 1 0.801 0.753 0.083 6.837
Histologic grade (2) -38.940 17691.716 0.000 1 0.998 0.000 0.000 .
Clinical stage (1) 38.435 11334.026 0.000 1 0.997 4.922E16 0.000 .
Clinical stage (2) 39.230 11334.026 0.000 1 0.997 1.090E17 0.000 .
Clinical stage (3) 59.653 26786.984 0.000 1 0.998 8.068E25 0.000 .
Surgical treatment (1) -21.372 7765.255 0.000 1 0.998 0.000 0.000 .
Surgical treatment (2) -22.214 7765.255 0.000 1 0.998 0.000 0.000 .
Surgical treatment (3) -0.010 28905.871 0.000 1 1.000 0.990 0.000 .
Surgical treatment (4) -2.220 24586.884 0.000 1 1.000 0.109 0.000 .
Surgical treatment (5) -6.967 41032.131 .000 1 1.000 0.001 0.000 .
Tumor distance from surgical  
edge of the preparation -0.176 0.127 1.919 1 0.166 0.839 0.654 1.076
Depth of invasion 0.049 0.063 0.608 1 0.436 1.051 0.928 1.190
Lymph node status 3.290 0.890 5.46 1 0.020 8.28 2.010 15.283
Adjuvant radiotherapy  
and chemotherapy -3.330 1.353 6.056 1 0.014 27.941 1.970 396.357
Tumor size -0.011 0.041 0.076 1 0.783 0.989 0.913 1.071
Histologic type according to level of differentiation: well/poor; histologic grade: GI, GII, clinical stage according to FIGO; mode of 
 surgical treatment: 1) excision; 2) vulvectomy with bilateral lymphadenectomy; 3) radical vulvectomy; 4) hemivulvectomy; 5) vulvectomy 
simplex
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adjuvant therapy, i.e. the patients having received adju-
vant therapy would have a 28-fold greater probability 
to die. Lymph node status was another significant fac-
tor, i.e. the patients with positive lymph nodes would 
have an 8.3-fold greater chance of lethal outcome. 
Other factors, although important for the overall 
model, did not contribute to predicting death individ-
ually (Table 2).
Discussion
The survey involved 59 respondents. The highest in-
cidence of vulvar cancer was recorded between 65 and 
76 years (23%), which is consistent with literature data. 
According to Cárcamo et al., the five-year overall sur-
vival rate for vulvar cancer was 41%. In our research, the 
five-year overall survival was 72.9%, illustrating how 
survival has increased compared to previous studies5.
According to Raspagliesi et al., age is a statistically 
significant prognostic factor3. The study by Sun et al. 
confirmed previous researches, and they also suggest 
univariate and multivariate prognostic significance of 
age6. In our research, age did not prove to be a statisti-
cally significant factor (p=0.654).
The most commonly reported histologic type of tu-
mor is squamous cell carcinoma (96%) with survival of 
about 71.9%. Univariate analysis showed that histo-
logic type was not statistically significant in prognosis, 
and multivariate analysis showed that histologic type 
was not independently prognostically significant 
(p=0.572). In a number of studies, histologic type was 
statistically significant for prognosis on univariate 
analysis2-6.
In our study, FIGO stage II was detected in 37% of 
women with vulvar cancer. Overall survival was 100% 
in FIGO stage I 63.6% in FIGO II, 60% in FIGO III, 
and 0% in FIGO IV. In the study by Konidaris et al., 
survival was 93% in FIGO stage I, 85% in FIGO II, 
50% in FIGO III, and 0% in FIGO IV7. In our re-
search, FIGO stage proved to be a statistically signifi-
cant factor (p=0.001). There was a significant differ-
ence in survival between FIGO stage I and all other 
FIGO stages, but clinical stage was not shown as an 
independent factor on multivariate analysis7. Coleman 
et al. showed that FIGO stage was a statistically sig-
nificant factor on univariate analysis, and unlike our 
study, showed FIGO stage to be an independent prog-
nostic factor on multivariate analysis8.
According to the study conducted by Paladini et 
al.9, tumor size was statistically significant in the prog-
nosis, whereas our study showed that tumor size was 
not a prognostically significant factor. In our study, the 
largest number of women (39%) had tumor size of 1-2 
cm with 80% survival.
Our results showed well-differentiated tumors 
(G1) to be the most common histopathologic finding 
with 72.1% survival. Difference in survival according 
to histologic grade showed no statistical significance 
on either univariate or multivariate analysis (p=0.320). 
Some other studies report on histologic grade to be 
statistically significant in the prognosis of vulvar can-
cer on univariate analysis and an independent prog-
nostic factor on multivariate analysis3.
Considering the type of surgical treatment as a 
prognostic factor, our data were not consistent with 
other studies, which report on the mode of surgical 
treatment to be a statistically significant factor in the 
prognosis of vulvar cancer7, whereas in our study uni-
variate analysis suggested that the method of surgical 
treatment was not a statistically significant factor 
(p=0.222).
According to Woelber et al.10, tumor distance from 
surgical edge of the preparation has a statistically sig-
nificant role in survival. In our study, the best survival 
was recorded in patients whose tumor was more dis-
tant from the edge of the preparation (about 70%); 
however, tumor distance from the edge of the prepara-
tion did not prove to be statistically significant on ei-
ther univariate or multivariate analysis (p=0.122)
According to the study by Nicoletto et al.11, the 
depth of tumor invasion in stroma is a statistically sig-
nificant factor in prognosis, and a similar study showed 
the depth of invasion to be an independent prognostic 
factor in diagnosis12. In our study, the depth of inva-
sion did not prove to be a statistically significant factor 
(p=0.675) or an independent factor.
According to the research conducted by Chan et 
al.12, lymph node status also has an independent prog-
nostic significance. Recent researches confirm the previ-
ous ones, and they also speak of prognostic significance, 
seen as univariate and independent prognostic signifi-
cance, seen as multivariate9,13,14. In our study, lymph 
node status was also shown to be a statistically signifi-
cant and independent prognostic factor (p=0.045).
According to literature data, the more lymph nodes 
are affected, the worse survival is13-17. According to the 
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study by Tan et al., adjuvant radiotherapy and chemo-
therapy proved to be a statistically significant factor18. 
Our study showed the same results. The patients that 
received adjuvant irradiation and chemotherapy had 
poorer survival than those that did not receive it. One 
of the reasons is that patients having received adjuvant 
radiotherapy and chemotherapy had been detected at a 
later stage of the disease, with greater tumor size and 
greater depth of tumor invasion in the stroma, with 
positive lymph nodes, so that all factors together con-
tributed to poor survival.
Conclusion
Univariate analysis showed the lymph node status, 
adjuvant radiotherapy and chemotherapy, along with 
clinical staging of the disease to be statistically signifi-
cant prognostic factors for survival of vulvar cancer 
patients. On multivariate analysis, the lymph node sta-
tus, adjuvant radiotherapy and chemotherapy were 
positive independent prognostic factors for survival of 
vulvar cancer patients.
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Sažetak
PROGNOSTIČKI ČIMBENICI RAKA VULVE
I. Miljanović-Špika, M. Drežnjak Madunić, Z. Topolovec, D. Kujadin Kenjereš i D. Vidosavljević
Cilj ove retrospektivne studije bio je istražiti utjecaj kliničkih, patoloških, citoloških i terapijskih prognostičkih čimbeni-
ka na ishod liječenja i preživljavanje bolesnica s karcinomom vulve te utvrditi prognostičko značenje svakog od pojedinačnih 
čimbenika kao i njihovo uzajamno značenje i utjecaj na sveukupno preživljavanje. Istraživanje je obuhvatilo bolesnice lije čene 
od karcinoma vulve u razdoblju od 2000. do 2011. godine na Klinici za ginekologiju i porodništvo KBC-a Osijek. Retro-
spektivna analiza je obuhvaćala njihove povijesti bolesti zajedno s patološkim i citološkim nalazima te nalazima onkologa. 
Studija je obuhvatila 59 bolesnica u dobi od 45 do 88 godina. Dijagnoza se temeljila na patološkom i citološkom statusu i 
stadiju. Kao statistički značajni prognostički čimbenici preživljavanja bolesnica s karcinomom vulve u univarijatnoj analizi 
pokazali su se status limfnih čvorova, adjuvantna radioterapija, kemoterapija i klinički stadij bolesti. U multivarijatnoj analizi 
neovisnih prognostičkih čimbenika za preživljavanje bolesnica s karcinomom vulve, status limfnih čvorova, pomoćna tera pija 
zračenjem i kemoterapija smatrani su pozitivnim prognostičkim čimbenicima.
Ključne riječi: Vulva; Rak; Preživljavanje; Kemoterapija; Stadij
